New hope for Hard-to-Treat prostate cancer: first human trial launches

NCT ID NCT06318273

Ongoing Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called ABBV-969 in men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals are to check the drug's safety and find the best dose. About 230 participants worldwide will receive the drug through an IV, and the study will last up to 3 years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

AdventHealth Orlando /ID# 261686

Orlando, Florida, 32803, United States
Ballarat Base Hospital /ID# 264294

Ballarat, Victoria, 3350, Australia
Carolina BioOncology Institute /ID# 261602

Huntersville, North Carolina, 28078, United States
Centre Hospitalier de l'Universite de Montreal (CHUM) /ID# 270890

Montreal, Quebec, H2X 0C1, Canada
Centre Leon Berard /ID# 270605

Lyon, Rhone, 69373, France
Centre Oscar Lambret /ID# 270602

Lille, Nord, 59000, France
Chris O'Brien Lifehouse /ID# 261731

Camperdown, New South Wales, 2050, Australia
City of Hope /ID# 262059

Duarte, California, 91010, United States
Hadassah Medical Center-Hebrew University /ID# 261771

Jerusalem, 91120, Israel
Hospital Universitario HM Sanchinarro /ID# 271345

Madrid, 28050, Spain
Hospital Universitario Vall de Hebron /ID# 270889

Barcelona, 08035, Spain
Hospital Universitario Virgen del Rocio /ID# 270617

Seville, 41013, Spain
Institut Gustave Roussy /ID# 270603

Villejuif, Île-de-France Region, 94800, France
Kyoto University Hospital /ID# 261861

Kyoto, Kyoto, 606-8507, Japan
Lifespan Cancer Institute at Rhode Island Hospital /ID# 261687

Providence, Rhode Island, 02903-4923, United States
McGill University Health Centre - Glen Site. /ID# 271275

Montreal, Quebec, H4A 3J1, Canada
NEXT Oncology /ID# 261601

San Antonio, Texas, 78229, United States
National Cancer Center Hospital /ID# 261698

Chuo-ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East /ID# 261606

Kashiwa-shi, Chiba, 277-8577, Japan
Rambam Health Care Campus- Haifa /ID# 261770

Haifa, 3109601, Israel
START Midwest /ID# 264295

Grand Rapids, Michigan, 49546, United States
St Vincent's Hospital /ID# 264293

Fitzroy, Victoria, 3065, Australia
The Chaim Sheba Medical Center /ID# 261772

Ramat Gan, Tel Aviv, 5265601, Israel
Univ California, San Francisco /ID# 261715

San Francisco, California, 94143-2204, United States
University of Chicago Medical Center /ID# 261605

Chicago, Illinois, 60637, United States
Yale University School of Medicine /ID# 262234

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.